Eliane Miyaji

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7989722/publications.pdf

Version: 2024-02-01

63 papers	2,035 citations	185998 28 h-index	253896 43 g-index
64 all docs	64 docs citations	64 times ranked	1846 citing authors

#	Article	IF	Citations
1	Controlled Human Infection and Rechallenge with Streptococcus pneumoniae Reveals the Protective Efficacy of Carriage in Healthy Adults. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 855-864.	2.5	166
2	Induction of systemic and mucosal immune response and decrease in Streptococcus pneumoniae colonization by nasal inoculation of mice with recombinant lactic acid bacteria expressing pneumococcal surface antigen A. Microbes and Infection, 2006, 8, 1016-1024.	1.0	101
3	Characterization of Protective Mucosal and Systemic Immune Responses Elicited by Pneumococcal Surface Protein PspA and PspC Nasal Vaccines against a Respiratory Pneumococcal Challenge in Mice. Vaccine Journal, 2009, 16, 636-645.	3.2	97
4	Recombinant Mycobacterium bovis BCG Expressing Pertussis Toxin Subunit S1 Induces Protection against an Intracerebral Challenge with Live Bordetella pertussis in Mice. Infection and Immunity, 2000, 68, 4877-4883.	1.0	91
5	Serotype-independent pneumococcal vaccines. Cellular and Molecular Life Sciences, 2013, 70, 3303-3326.	2.4	78
6	Immunization of Mice with Single PspA Fragments Induces Antibodies Capable of Mediating Complement Deposition on Different Pneumococcal Strains and Cross-Protection. Vaccine Journal, 2010, 17, 439-446.	3.2	77
7	The immunising effect of pneumococcal nasopharyngeal colonisation; protection against future colonisation and fatal invasive disease. Immunobiology, 2010, 215, 251-263.	0.8	76
8	Fusion Proteins Containing Family 1 and Family 2 PspA Fragments Elicit Protection against Streptococcus pneumoniae That Correlates with Antibody-Mediated Enhancement of Complement Deposition. Infection and Immunity, 2007, 75, 5930-5938.	1.0	69
9	Recognition of pneumococcal isolates by antisera raised against PspA fragments from different clades. Journal of Medical Microbiology, 2008, 57, 273-278.	0.7	58
10	Pulmonary dry powder vaccine of pneumococcal antigen loaded nanoparticles. International Journal of Pharmaceutics, 2015, 495, 903-912.	2.6	58
11	Expression and characterization of cholera toxin Bâ€"pneumococcal surface adhesin A fusion protein in Escherichia coli: ability of CTB-PsaA to induce humoral immune response in mice. Biochemical and Biophysical Research Communications, 2004, 321, 192-196.	1.0	57
12	Nasal immunization of mice with Lactobacillus casei expressing the Pneumococcal Surface Protein A: induction of antibodies, complement deposition and partial protection against Streptococcus pneumoniae challenge. Microbes and Infection, 2008, 10, 481-488.	1.0	52
13	Optimized Immune Response Elicited by a DNA Vaccine Expressing Pneumococcal Surface Protein A Is Characterized by a Balanced Immunoglobulin G1 (IgG1)/IgG2a Ratio and Proinflammatory Cytokine Production. Vaccine Journal, 2008, 15, 499-505.	3.2	51
14	Recombinant Mycobacterium bovis BCG Expressing the Sm14 Antigen of Schistosoma mansoni Protects Mice from Cercarial Challenge. Infection and Immunity, 2004, 72, 3336-3343.	1.0	50
15	Polysaccharide-Specific Memory B Cells Predict Protection against Experimental Human Pneumococcal Carriage. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1523-1531.	2.5	49
16	Analysis of Serum Cross-Reactivity and Cross-Protection Elicited by Immunization with DNA Vaccines against Streptococcus pneumoniae Expressing PspA Fragments from Different Clades. Infection and Immunity, 2002, 70, 5086-5090.	1.0	40
17	Intranasal Immunization with the Cholera Toxin B Subunit-Pneumococcal Surface Antigen A Fusion Protein Induces Protection against Colonization with Streptococcus pneumoniae and Has Negligible Impact on the Nasopharyngeal and Oral Microbiota of Mice. Infection and Immunity, 2006, 74, 4939-4944.	1.0	40
18	Combination of Pneumococcal Surface Protein A (PspA) with Whole Cell Pertussis Vaccine Increases Protection Against Pneumococcal Challenge in Mice. PLoS ONE, 2010, 5, e10863.	1.1	40

#	Article	IF	Citations
19	Mucosal immunization with PspA (Pneumococcal surface protein A)-adsorbed nanoparticles targeting the lungs for protection against pneumococcal infection. PLoS ONE, 2018, 13, e0191692.	1.1	40
20	Genetic Diversity of PspA Types among Nasopharyngeal Isolates Collected during an Ongoing Surveillance Study of Children in Brazil. Journal of Clinical Microbiology, 2006, 44, 2838-2843.	1.8	39
21	PsaA (pneumococcal surface adhesin A) and PspA (pneumococcal surface protein A) DNA vaccines induce humoral and cellular immune responses against Streptococcus pneumoniae. Vaccine, 2001, 20, 805-812.	1.7	38
22	Photorepair prevents ultraviolet-induced apoptosis in human cells expressing the marsupial photolyase gene. Cancer Research, 2000, 60, 2458-63.	0.4	38
23	Induction of Neutralizing Antibodies against Diphtheria Toxin by Priming with Recombinant Mycobacterium bovis BCG Expressing CRM197, a Mutant Diphtheria Toxin. Infection and Immunity, 2001, 69, 869-874.	1.0	37
24	Modulation of nasopharyngeal innate defenses by viral coinfection predisposes individuals to experimental pneumococcal carriage. Mucosal Immunology, 2016, 9, 56-67.	2.7	36
25	Protection against nasal colonization with Streptococcus pneumoniae by parenteral immunization with a DNA vaccine encoding PspA (Pneumococcal surface protein A). Microbial Pathogenesis, 2010, 48, 205-213.	1.3	35
26	Nasal immunization of mice withLactobacillus caseiexpressing the pneumococcal surface protein C primes the immune system and decreases pneumococcal nasopharyngeal colonization in mice. FEMS Immunology and Medical Microbiology, 2011, 62, 263-272.	2.7	35
27	Expression ofStreptococcus pneumoniaeantigens, PsaA (pneumococcal surface antigen A) and PspA (pneumococcal surface protein A) byLactobacillus casei. FEMS Microbiology Letters, 2003, 227, 25-31.	0.7	34
28	Bordetella pertussis monophosphoryl lipid A as adjuvant for inactivated split virion influenza vaccine in mice. Vaccine, 2009, 27, 4219-4224.	1.7	34
29	Aerobic exercise attenuates pulmonary inflammation induced byStreptococcus pneumoniae. Journal of Applied Physiology, 2014, 117, 998-1007.	1.2	29
30	Trends in adjuvant development for vaccines: DAMPs and PAMPs as potential new adjuvants. Brazilian Journal of Medical and Biological Research, 2011, 44, 500-513.	0.7	27
31	Adjuvant activity of Mycobacterium bovis BCG expressing CRM197 on the immune response induced by BCG expressing tetanus toxin fragment C. Vaccine, 2004, 22, 740-746.	1.7	25
32	Production of H5N1 (NIBRG-14) inactivated whole virus and split virion influenza vaccines and analysis of immunogenicity in mice using different adjuvant formulations. Vaccine, 2010, 28, 2505-2509.	1.7	24
33	Mapping of Epitopes Recognized by Antibodies Induced by Immunization of Mice with PspA and PspC. Vaccine Journal, 2014, 21, 940-948.	3.2	22
34	Protective efficacy ofpspA(pneumococcal surface protein A)-based DNA vaccines: contribution of both humoral and cellular immune responses. FEMS Immunology and Medical Microbiology, 2003, 37, 53-57.	2.7	19
35	Comparison of the pulmonary response against lethal and non-lethal intranasal challenges with two different pneumococcal strains. Microbial Pathogenesis, 2009, 47, 157-163.	1.3	18
36	Controlled Inflammatory Responses in the Lungs Are Associated with Protection Elicited by a Pneumococcal Surface Protein A-Based Vaccine against a Lethal Respiratory Challenge with Streptococcus pneumoniae in Mice. Vaccine Journal, 2012, 19, 1382-1392.	3.2	18

#	Article	IF	Citations
37	Characterization of the antibody response elicited by immunization with pneumococcal surface protein A (PspA) as recombinant protein or DNA vaccine and analysis of protection against an intranasal lethal challenge with Streptococcus pneumoniae. Microbial Pathogenesis, 2012, 53, 243-249.	1.3	18
38	Cross-Reactivity of Antipneumococcal Surface Protein C (PspC) Antibodies with Different Strains and Evaluation of Inhibition of Human Complement Factor H and Secretory IgA Binding via PspC. Vaccine Journal, 2012, 19, 499-507.	3.2	17
39	Production and purification of an untagged recombinant pneumococcal surface protein A (PspA4Pro) with high-purity and low endotoxin content. Applied Microbiology and Biotechnology, 2017, 101, 2305-2317.	1.7	17
40	Pneumococcal Vaccines: Past Findings, Present Work, and Future Strategies. Vaccines, 2021, 9, 1338.	2.1	17
41	DNA vaccines expressing pneumococcal surface protein A (PspA) elicit protection levels comparable to recombinant protein. Journal of Medical Microbiology, 2006, 55, 375-378.	0.7	16
42	Economical Value of Vaccines for the Developing Countriesâ€"The Case of Instituto Butantan, a Public Institution in Brazil. PLoS Neglected Tropical Diseases, 2011, 5, e1300.	1.3	13
43	Mycobacterial codon optimization of the gene encoding the Sm14 antigen ofSchistosoma mansoniin recombinantMycobacterium bovisBacille Calmette-GuÃƒÂ©rin enhances protein expression but not protection against cercarial challenge in mice. FEMS Immunology and Medical Microbiology, 2006, 48, 132-139.	2.7	12
44	Optimizing Expression of Streptococcus pneumoniae Surface Protein a, PspA: Serocross-Reactivity within Families of Antisera Induced Against Clades 1 and 3. Molecular Biotechnology, 2007, 37, 146-154.	1.3	12
45	Evaluation of a Vaccine Formulation against Streptococcus pneumoniae Based on Choline-Binding Proteins. Vaccine Journal, 2015, 22, 213-220.	3.2	12
46	DNA vaccines based on genetically detoxified derivatives of pneumolysin fail to protect mice against challenge withStreptococcus pneumoniae. FEMS Immunology and Medical Microbiology, 2006, 46, 291-297.	2.7	10
47	Protection Elicited by Nasal Immunization with Recombinant Pneumococcal Surface Protein A (rPspA) Adjuvanted with Whole-Cell Pertussis Vaccine (wP) against Co-Colonization of Mice with Streptococcus pneumoniae. PLoS ONE, 2017, 12, e0170157.	1.1	10
48	Evaluation of polymer choice on immunogenicity of chitosan coated PLGA NPs with surface-adsorbed pneumococcal protein antigen PspA4Pro. International Journal of Pharmaceutics, 2021, 599, 120407.	2.6	10
49	Intradermal Immunization of Mice with Cholera Toxin B-Pneumococcal Surface Protein A Fusion Protein Is Protective against Intraperitoneal Challenge with Streptococcus pneumoniae. Infection and Immunity, 2005, 73, 3810-3813.	1.0	9
50	Progress in mucosal immunization for protection against pneumococcal pneumonia. Expert Review of Vaccines, 2019, 18, 781-792.	2.0	8
51	ULTRAVIOLETâ€INDUCED CELL DEATH IS INDEPENDENT OF DNA REPLICATION IN RAT KANGAROO CELLS. Photochemistry and Photobiology, 1995, 61, 454-458.	1.3	7
52	Impaired expression of CXCL5 and matrix metalloproteinases in the lungs of mice with high susceptibility to Streptococcus pneumoniae infection. Immunity, Inflammation and Disease, 2018, 6, 128-142.	1.3	7
53	Photoreversion of ultraviolet induced apoptosis in Rat Kangaroo cells. Apoptosis: an International Journal on Programmed Cell Death, 1996, 1, 153-160.	2.2	6
54	Pneumococcal Surface Protein A-Hybrid Nanoparticles Protect Mice from Lethal Challenge after Mucosal Immunization Targeting the Lungs. Pharmaceutics, 2022, 14, 1238.	2.0	6

#	Article	IF	Citations
55	Human BCLâ€2 Expression Delays Ultravioletâ€Induced Apoptosis in Marsupial Cells. Photochemistry and Photobiology, 1998, 68, 719-724.	1.3	5
56	Pneumococcal Surface Protein A does not affect the immune responses to a combined diphtheria tetanus and pertussis vaccine in mice. Vaccine, 2013, 31, 2465-2470.	1.7	5
57	Pertussis Toxin Improves Immune Responses to a Combined Pneumococcal Antigen and Leads to Enhanced Protection against Streptococcus pneumoniae. Vaccine Journal, 2014, 21, 972-981.	3.2	5
58	Efficacy of a Protein Vaccine and a Conjugate Vaccine Against Co-Colonization with Vaccine-Type and Non-Vaccine Type Pneumococci in Mice. Pathogens, 2020, 9, 278.	1.2	5
59	Elicitation of Mucosal Immunity by Proteins of Streptococcus pneumoniae. Advances in Oto-Rhino-Laryngology, 2011, 72, 25-27.	1.6	4
60	Serum levels of anti-PspA and anti-PspC IgG decrease with age and do not correlate with susceptibility to experimental human pneumococcal colonization. PLoS ONE, 2021, 16, e0247056.	1.1	3
61	Evaluation of inactivated Bordetella pertussis as a delivery system for the immunization of mice with Pneumococcal Surface Antigen A. PLoS ONE, 2020, 15, e0228055.	1.1	2
62	The Modified Surface Killing Assay Distinguishes between Protective and Nonprotective Antibodies to PspA. MSphere, 2019, 4, .	1.3	1
63	Human Bcl-2 expression delays ultraviolet-induced apoptosis in marsupial cells. Photochemistry and Photobiology, 1998, 68, 719-24.	1.3	0